In a high-profile showdown Tuesday with Sen. Bernie Sanders’ Senate health committee, Novo Nordisk CEO Lars Fruergaard ...

Lawmakers are set to scrutinize the high cost of weight loss and diabetes drugs, which depending upon your insurance can ...

Jorgensen is set to testify before a Senate committee on Tuesday in a hearing focused on U.S. prices for its widely popular ...

The CEO of Novo Nordisk will testify in the Senate HELP Committee tomorrow about the cost of popular diabetes and weight loss ...

As the Senate Committee on Health, Education, Labor and Pensions (HELP) gears up for a hearing tomorrow titled “Why Is Novo ...

Hearing on weight loss drug prices will feature CEO of Novo Nordisk and comes after threats to subpoena company executives.

It's the second lawsuit to be filed this year in Maine against insurance carriers that limit coverage of popular drugs like ...

Ahead of a Senate hearing centered on high prices for Novo Nordisk’s in-demand semaglutide medications, lawmakers are ...

Millions of older Americans with obesity could potentially get Medicare's help with the hefty price of a weight-loss medication in order to reduce ...

According to the Journal, the GLP-1 "pricing fight" began in late 2023, when Lilly priced Zepbound at $1,060 per month, or 20% lower than Novo Nordisk's Wegovy. Analysts told the newspaper that prices ...

Developed to treat diabetes, drugs like Ozempic now help fight obesity. Scientists newly honoured for working on them recall ...

Ozempic and Wegovy are making so much money for Novo Nordisk A/S that their cumulative sales will soon surpass the ...